The oxygen evolution reaction under neutral conditions remains a significant challenge due to sluggish kinetics and catalyst instability, largely stemming from inefficient proton management. Inspired Show more
The oxygen evolution reaction under neutral conditions remains a significant challenge due to sluggish kinetics and catalyst instability, largely stemming from inefficient proton management. Inspired by the proton-coupled electron transfer (PCET) networks in the oxygen-evolving complex of photosystem II, we report the rational design of two bioinspired cubane-type tetranuclear copper catalysts, Cu4(LGly)4 and Cu4(LGlu)4, functionalized with amino acid derivatives. Electrochemical studies reveal that the glutamate-modified Cu4(LGlu)4 outperforms its glycine counterpart, achieving a remarkable turnover frequency (TOF) of 9.64 ± 0.07 s-1 at a low overpotential of 0.63 V in phosphate buffer solution (pH 7.30). Differential pulse voltammetry and mechanistic investigations indicate a PCET nature for the copper redox transitions. Density functional theory calculations demonstrate that the carboxylate group of the glutamate residue acts as an intrinsic proton relay, significantly lowering the energy barrier for the critical O-O bond formation step. Furthermore, a photovoltaic-electrocatalytic (PV-EC) device utilizing the Cu4(LGlu)4 anode achieves a solar-to-hydrogen (STH) conversion efficiency of 10.24% under neutral conditions, one of the highest reported values without a strong alkaline environment. This work underscores the critical role of second-sphere proton-transfer functionality in designing efficient molecular catalysts for PCET-driven energy conversion reactions. Show less
Necrotizing enterocolitis (NEC) involves intestinal epithelial damage and inflammatory response and is associated with high morbidity and mortality in infants. To improve therapeutic prospects, elucid Show more
Necrotizing enterocolitis (NEC) involves intestinal epithelial damage and inflammatory response and is associated with high morbidity and mortality in infants. To improve therapeutic prospects, elucidating underlying molecular mechanisms of intestinal epithelial damage during NEC is of the essence. Poly (ADP-ribose) polymerase 1 (PARP1)-dependent parthanatos is a programmed inflammatory cell death. In the present study, the presence of parthanatos-associated proteins PARP1 and poly (ADP-ribose) (PAR), along with high expression of DNA damage-associated biomarkers, 8-hydroxy-2’-deoxyguanosine (8-OHdG) and phosphorylation of histone H2AX (γH2AX), were discovered in the intestinal tissues of NEC infants. Additionally, the upregulated expression of PARP1 and PAR in NEC intestinal tissues correlated distinctly with clinical indices indicative of NEC incidence and severity. Furthermore, we demonstrated that inhibiting the expression of parthanatos-associated proteins, by either pharmacological blockage using 3-aminobenzamide (3-AB), an inhibitor of PARP1, or genetic knockout using Parp1-deficient mice, resulted in substantial improvements in both histopathological severity scores associated with intestinal injury and inflammatory reactions. Moreover, in an in vitro NEC model, reactive oxygen species (ROS)-induced DNA damage promoted the formation of PAR and nuclear translocation of apoptosis-inducing factor (AIF), thus activating PARP1-dependent parthanatos in Caco-2 cells and human intestinal organoids. Our work verifies a previously unexplored role for parthanatos in intestinal epithelial damage during NEC and suggests that inhibition of parthanatos may serve as a potential therapeutic strategy for intervention of NEC. Show less
Developing novel therapeutics often follows three steps: target identification, design of strategies to suppress target activity and drug development to implement the strategies. In this review, we re Show more
Developing novel therapeutics often follows three steps: target identification, design of strategies to suppress target activity and drug development to implement the strategies. In this review, we recount the evidence identifying the basic leucine zipper transcription factors ATF5, CEBPB, and CEBPD as targets for brain and other malignancies. We describe strategies that exploit the structures of the three factors to create inhibitory dominant-negative (DN) mutant forms that selectively suppress growth and survival of cancer cells. We then discuss and compare four peptides (CP-DN-ATF5, Dpep, Bpep and ST101) in which DN sequences are joined with cell-penetrating domains to create drugs that pass through tissue barriers and into cells. The peptide drugs show both efficacy and safety in suppressing growth and in the survival of brain and other cancers in vivo, and ST101 is currently in clinical trials for solid tumors, including GBM. We further consider known mechanisms by which the peptides act and how these have been exploited in rationally designed combination therapies. We additionally discuss lacunae in our knowledge about the peptides that merit further research. Finally, we suggest both short- and long-term directions for creating new generations of drugs targeting ATF5, CEBPB, CEBPD, and other transcription factors for treating brain and other malignancies. Show less